For
UK
audiences
The professional's guide to product selection
The professional's guide to product selection
Mucolytic to facilitate expectoration by reducing sputum viscosity.
• Over 18 years: 300 mg, twice daily for up to 10 days.
For symptomatic treatment of acute exacerbations of chronic bronchitis.
The Scottish Medicines Consortium stated in October 2007 that erdosteine (Erdotin) is not recommended for the symptomatic treatment of acute exacerbations of chronic bronchitis. For additional information see: https://www.scottishmedicines.org.uk/medicines-advice/erdosteine-300mg-capsules-erdotin-fullsubmission-41507/
Manufactorer recomments to avoid use in te case of hepatic or renal impairment or pregnancy and breast feeding.
Capsules
Capsules
Erdotin capsules, 300 mg, 20 pack
Reduction of sputum viscosity.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic to facilitate expectoration.
• Child 2–4 years: 62.5–125 mg, 4 times daily
• Child 5–11 years: 250 mg, 3 times daily
• Over 12 years: initially 2.25 g daily in divided doses, then 1.5 g daily in divided doses as condition improves.
Mucolytic
Osmohale is used for an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness, a clinical feature of some respiratory conditions such as asthma.
Contraindications: Use with caution in renal impairment and to avoid in pregnancy. The Osmohale test should not be used in patients below 6 years of age due to their inability to provide reproducible spirometric measurements.
There is limited information on the use of Osmohale in patients 6-18 years of age therefore Osmohale is not recommended in this population.
Dose: See manufacturers’ instructions for more information. The test should be repeated until the patient has a positive response or 635 mg has been administered.